1.52 Indemnified Party has the meaning set forth in Section 8.3 (Indemnification Procedures).
1.53 Indemnify has the meaning set forth in Section 8.1 (Indemnification by Adimab).
1.54 Indemnifying Party has the meaning set forth in Section 8.3 (Indemnification Procedures).
1.55 Indemnitees has the meaning set forth in Section 8.3 (Indemnification Procedures).
1.56 Initial CoV Antibody has the meaning set forth in Section 1.11(a) (Adimab CoV Antibody).
1.57 Know-How means all proprietary technical information and know-how in any tangible or intangible form, including (a) inventions, discoveries, trade secrets, data, specifications, instructions, processes, formulae, materials (including cell lines, vectors, plasmids, nucleic acids and the like), methods, protocols, expertise and any other technology, including the applicability of any of the foregoing to formulations, compositions or products or to their manufacture, development, registration, use or marketing or to methods of assaying or testing them or processes for their manufacture, formulations containing them or compositions incorporating or comprising them, and (b) all data, instructions, processes, formulae, strategies, and expertise, whether biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, analytical, or otherwise and whether related to safety, quality control, manufacturing or other disciplines; that, in each case ((a) and (b)), are not in the public domain. Notwithstanding the foregoing, Know-How excludes Patent claims.
1.58 License has the meaning set forth in Section 3.1(b) (License).
1.59 Licensee means a Third Party to whom Adagio or its Affiliate has granted, directly or indirectly through one or more tiers of sublicense, a license, sublicense or other right to develop, manufacture, or commercialize any CoV Antibody or Product; but specifically excluding any Third Party contract service provider. For clarity, licensees of CoV Antibody Patents and sublicensees of the License shall be Licensees.
1.60 Licensee Agreement has the meaning set forth in Section 3.2 (Licensees and Sublicensees).
1.61 Losses has the meaning set forth in Section 8.1 (Indemnification by Adimab).
1.62 Major European Market means any of [***].
1.63 Major Market means any of the [***].
1.64 Marketing Approval means, within any given country, approval to market and sell a Product legally as a drug or biologic, including approval of an NDA. Pricing approval need not be obtained in order for Marketing Approval to be achieved.